| Targeting STING with covalent small-molecule inhibitors SM Haag, MF Gulen, L Reymond, A Gibelin, L Abrami, A Decout, ... Nature 559 (7713), 269-273, 2018 | 853 | 2018 |
| Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity B Hiller, M Achleitner, S Glage, R Naumann, R Behrendt, A Roers Journal of Experimental Medicine 209 (8), 1419-1426, 2012 | 267 | 2012 |
| TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner A Ablasser, I Hemmerling, JL Schmid-Burgk, R Behrendt, A Roers, ... The Journal of Immunology 192 (12), 5993-5997, 2014 | 259 | 2014 |
| Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response R Behrendt, T Schumann, A Gerbaulet, LA Nguyen, N Schubert, ... Cell reports 4 (4), 689-696, 2013 | 168 | 2013 |
| Loss of Trex1 in dendritic cells is sufficient to trigger systemic autoimmunity K Peschke, M Achleitner, K Frenzel, A Gerbaulet, SR Ada, N Zeller, ... The Journal of Immunology 197 (6), 2157-2166, 2016 | 87 | 2016 |
| Macrophage and T cell produced IL-10 promotes viral chronicity K Richter, G Perriard, R Behrendt, RA Schwendener, V Sexl, R Dunn, ... PLoS pathogens 9 (11), e1003735, 2013 | 84 | 2013 |
| SCA-1 expression level identifies quiescent hematopoietic stem and progenitor cells MNF Morcos, KB Schoedel, A Hoppe, R Behrendt, O Basak, HC Clevers, ... Stem Cell Reports 8 (6), 1472-1478, 2017 | 64 | 2017 |
| Phosphorylation of murine SAMHD1 regulates its antiretroviral activity S Wittmann, R Behrendt, K Eissmann, B Volkmann, D Thomas, T Ebert, ... Retrovirology 12, 1-15, 2015 | 56 | 2015 |
| Deregulated type I IFN response in TREX1-associated familial chilblain lupus K Peschke, F Friebe, N Zimmermann, T Wahlicht, T Schumann, ... The Journal of investigative dermatology 134 (5), 1456, 2014 | 56 | 2014 |
| A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology T Prabakaran, A Troldborg, S Kumpunya, I Alee, E Marinković, ... EBioMedicine 66, 2021 | 53 | 2021 |
| Ribonucleotide excision repair is essential to prevent squamous cell carcinoma of the skin B Hiller, A Hoppe, C Haase, C Hiller, N Schubert, W Müller, MAM Reijns, ... Cancer research 78 (20), 5917-5926, 2018 | 46 | 2018 |
| Lack of Trex1 causes systemic autoimmunity despite the presence of antiretroviral drugs M Achleitner, M Kleefisch, A Hennig, K Peschke, A Polikarpova, R Oertel, ... The Journal of Immunology 199 (7), 2261-2269, 2017 | 41 | 2017 |
| Non-canonical caspase-1 signaling drives RIP2-dependent and TNF-α-mediated inflammation in vivo S Reinke, M Linge, HH Diebner, H Luksch, S Glage, A Gocht, ... Cell reports 30 (8), 2501-2511. e5, 2020 | 32 | 2020 |
| Mouse models for Aicardi–Goutières syndrome provide clues to the molecular pathogenesis of systemic autoimmunity R Behrendt, A Roers Clinical & Experimental Immunology 175 (1), 9-16, 2014 | 30 | 2014 |
| Linking NRP2 with EMT and chemoradioresistance in bladder cancer A Schulz, I Gorodetska, R Behrendt, S Fuessel, K Erdmann, S Foerster, ... Frontiers in Oncology 9, 1461, 2020 | 27 | 2020 |
| IκB kinase 2 is essential for IgE-induced mast cell de novo cytokine production but not for degranulation K Peschke, A Weitzmann, K Heger, R Behrendt, N Schubert, J Scholten, ... Cell reports 8 (5), 1300-1307, 2014 | 26 | 2014 |
| A neutralization assay for HIV-2 based on measurement of provirus integration by duplex real-time PCR R Behrendt, U Fiebig, S Norley, L Gürtler, R Kurth, J Denner Journal of virological methods 159 (1), 40-46, 2009 | 23 | 2009 |
| Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent manner T Schumann, SC Ramon, N Schubert, MA Mayo, M Hega, KI Maser, ... Journal of Experimental Medicine 220 (1), e20220829, 2022 | 22 | 2022 |
| Monocyte-derived macrophages aggravate pulmonary vasculitis via cGAS/STING/IFN-mediated nucleic acid sensing N Kessler, SF Viehmann, C Krollmann, K Mai, KM Kirschner, H Luksch, ... Journal of Experimental Medicine 219 (10), e20220759, 2022 | 21 | 2022 |
| Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions M Renn, E Bartok, T Zillinger, G Hartmann, R Behrendt Pharmacology & Therapeutics 228, 107931, 2021 | 21 | 2021 |
